Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

PURPOSE Most studies using various reverse-transcription polymerase chain reaction (RT-PCR) techniques reported that the detection of the AML1-ETO fusion transcript was a common finding in long-term complete remission (CR) in acute myeloid leukemia (AML) with t(8;21) translocation. However, larger prospective studies with interlaboratory quality control may be important to investigate more precisely the clinical usefulness of studying minimal residual disease with RT-PCR in t(8;21) AML. PATIENTS AND METHODS We collected 223 marrow samples from 51 patients with t(8;21) AML diagnosed in five centers and tested all samples by two different RT-PCR techniques (a nested technique and a one-step technique, with a sensitivity of 10(-6) and 10(-5), respectively) in two different laboratories. RESULTS Samples from 14 patients in long persistent CR (median follow-up duration, 112 months) were taken at least twice, and all were PCR-negative by both techniques. Samples were prospectively taken from 37 patients after achievement of first CR and/or second CR, before intensive consolidation treatment, and every 3 to 6 months after completion of therapy. Patients who converted to PCR negativity with the one-step technique (60%) or both techniques (48%) after CR achievement had a longer CR duration than those with persistently positive PCR results (two-sided log-rank test, P =.0001). Patients who became PCR-negative with the one-step technique before intensive consolidation (23%) had a lower relapse rate (11% v 72%) and a longer CR duration than those who remained persistently PCR-positive at that point (two-sided log-rank test, P =.0015). CONCLUSION Patients with AML with t(8;21) in long-term remission were all PCR-negative. In prospectively studied patients, a good correlation was found between negative PCR results and absence of relapse. Early negative results with the one-step RT-PCR technique, before consolidation treatment, seemed to carry an especially good prognosis, suggesting that RT-PCR analysis could help in choosing the type of consolidation therapy in patients with t(8;21) AML.

[1]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[2]  F. Mandelli,et al.  Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial , 1998 .

[3]  F. Mandelli,et al.  Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy. , 1998, Haematologica.

[4]  M. Caligiuri,et al.  Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. , 1997, Blood.

[5]  A. Elmaagacli,et al.  Detection of AML1/ETO fusion transcripts in patients with t(8;21) acute myeloid leukemia after allogeneic bone marrow transplantation or peripheral blood progenitor cell transplantation. , 1997, Blood.

[6]  C. Bloomfield,et al.  Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). , 1997, Blood.

[7]  C. Bloomfield,et al.  Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Caligiuri,et al.  Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. , 1996, Blood.

[9]  T. Haferlach,et al.  Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. , 1996, Leukemia.

[10]  K. Akashi,et al.  Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.

[11]  E. Macintyre,et al.  Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus? , 1996, Leukemia.

[12]  M. Ohki,et al.  Disappearance of AML1 ‐MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long‐term remission , 1995, British journal of haematology.

[13]  K. Akashi,et al.  Quantitative analysis of AML1/ET0 transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukaemia , 1995, British journal of haematology.

[14]  J. Rowley,et al.  AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. , 1995, Blood.

[15]  C. Wijmenga,et al.  Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. , 1995, Blood.

[16]  J. Friedl,et al.  AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. , 1994, Leukemia.

[17]  J. Rowley,et al.  The AML1 gene in the 8;21 and 3;21 translocations in chronic and acute myeloid leukemia. , 1994, Cold Spring Harbor symposia on quantitative biology.

[18]  N. Kamada,et al.  Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. , 1993, Blood.

[19]  J. Rowley,et al.  Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.

[20]  R. Warrell,et al.  Acute promyelocytic leukemia. , 1993, The New England journal of medicine.

[21]  J. Downing,et al.  An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. , 1993, Blood.

[22]  M. Ohki,et al.  The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1 , 1993 .

[23]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[24]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .